Text Size

Paroxetine markedly increases plasma concentrations of ophthalmic timolol; cyp2d6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops

Mäenpää J., Volotinen-Maja M., Kautiainen H., Neuvonen M., Niemi M., Neuvonen P.J., Backman J.T.


  • 2014
  • Drug Metabolism and Disposition
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Santen Oy, Tampere, Finland; Medcare Oy, Äänekoski, Finland; Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, P.O. Box 705, HUS, Helsinki, FI- 00029, Finland

Related Publications

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study

Panarelli J.F., Moster M.R., Garcia-Feijoo J., Flowers B.E., Baker N.D., Barnebey H.S., Grover D.S., Khatana A.K., Lee B., Nguyen T., Stiles M.C., Sadruddin O., Khaw P.T., Vold S., McFarland M., Stiles M., Stechschulte A., Strom A., Reynolds A., Noecker R., Thimons J., Khaimi M., Allen E., Sarkisian S., Barnebey H., Golez E., Feldman R., Bell N., Blieden L., Cantor L., WuDunn D., Catoira-Boyle Y., Chen H., Evans J., Martin E., Sozeri Y., Srivastava V., Wise R., Schwartz K., Grover D., Butler M., Emanuel M., Fellman R., Godfrey D., Smith O., Kornmann H., Khatana A., Hagee D., Kuhlman B., Zink J., Moster M., Dale E., Pro M., Baker D., Chambers M., Lehmann D., Caprioli J., Francis B., Giaconi J., Law S., Nouri-Mahdavi K., Coleman A., Flynn W., Rashid E., Reilly C., Rice R., Sidoti P., Panarelli J., Garg R., Tania Tai T.Y., Vinod K., Harizman N., Ritch R., Reiss G., Dewan V., Patel S., Sorenson C., Larsen C., Samuelson T., Hansen M., Barth T., Blakstad A., Buboltz M., Fahmy A., Fahmy M., Montealegre K., Mizener M., Whitted P., Lim M., Brandt J., Baik A., Jiang A., Brown S.V.L., Breunig A.C., Gorla M.S.R., Riss I., Feijoo G., Mendez Hernandez C., Martinez de la Casa J., Dupré Pelaez M., Fernandez Vidal A., García Sáenz S., Morales Fernandez L., Sáenz Francés F., Santos Bueso E., Perucho Gonzalez L., Beckers H.J.M., Kujovic S., Nardi M., Maglionico M.N., Nasini F., Passani A., Strouthidis N., Barton K., Clarke J., Gazzard G., Jayaram H., Khaw P., Papadopoulos M., Puertas R., Toth M., Lunt D., Triolo G., Kam R., Levine J., Flowers B., Nair U., Simmons S., Pokabla M., INN005 Study Group


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022